Publications
Where expertise meets impact
Berry doesn’t just follow industry standards — we set them. Our team of award-winning statisticians, journal editors, and regulatory advisors leads the field in Bayesian and adaptive clinical trial design. With research published in The New England Journal of Medicine, JAMA, and The Lancet, we’re driving innovation where it matters most.
Over 90% of our scientists published influential work this past year, advancing adaptive, Bayesian, and platform trial methodology. Our blend of academic rigor, regulatory insight, and real-world experience makes Berry a true authority in modern clinical trials.
Explore our most impactful peer-reviewed publications below.

JAMA
Methodology
The Hochberg Procedure for the Comparison of Multiple End Points
March 5, 2026
2026
DOI: 10.1001/jama.2026.0191
Journal of Thrombosis and Haemostasis
COVID-19
Deep Vein Thrombosis
Intermediate dose heparin thromboprophylaxis among critically ill patients with COVID-19: a randomized clinical trial
February 24, 2026
2026
10.1016/j.jtha.2026.03.006
Rare Diseases
Other Orphan Diseases
Complementary and alternative medicines and cannabis use among individuals with erythropoietic protoporphyria
January 1, 2026
2026
DOI: 10.1016/j.ymgme.2025.109703
BMJ Journals
Infectious Disease
Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomised controlled trial
December 12, 2025
2025
DOI: 10.1136/bmjopen-2025-107493
Methodology
Rare Diseases
Clinical trial design essentials for genetic counselors
November 26, 2025
2025
doi.org/10.1002/jgc4.70150
Annals of the American Thoracic Society
Methodology
Pulmonary
Opening the DOOR to More Informative Hospital Trials by Ranking Treatment Experiences
November 1, 2025
2025
doi: 10.1513/AnnalsATS.202412-1334IP
Thrombosis Research
COVID-19
Methodology
Safety and effectiveness of statins in hospitalized patients with COVID-19: Systematic review and collaborative meta-analysis of randomized controlled trials
September 20, 2025
2025
doi: 10.1016/j.thromres.2025.109484
Nature Medicine
Oncology
Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial
September 2, 2025
2025
DOI: 10.1038/s41591-025-03877-3
No results found.
There are no results with this criteria. Try changing your search.